Bioluminescent murine models of bacterial sepsis and scald wound infections for antimicrobial efficacy testing.

There are very few articles in the literature describing continuous models of bacterial infections that mimic disease pathogenesis in humans and animals without using separate cohorts of animals at each stage of disease. In this work, we developed bioluminescent mouse models of partial-thickness sca...

Full description

Bibliographic Details
Main Authors: Abiodun D Ogunniyi, Zlatko Kopecki, Elizabeth E Hickey, Manouchehr Khazandi, Emma Peel, Katherine Belov, Alexandra Boileau, Sanjay Garg, Henrietta Venter, Wei Yee Chan, Peter B Hill, Stephen W Page, Allison J Cowin, Darren J Trott
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC6047774?pdf=render
id doaj-4632a4228f75497d92cafa7122a9bfbe
record_format Article
spelling doaj-4632a4228f75497d92cafa7122a9bfbe2020-11-25T01:46:00ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01137e020019510.1371/journal.pone.0200195Bioluminescent murine models of bacterial sepsis and scald wound infections for antimicrobial efficacy testing.Abiodun D OgunniyiZlatko KopeckiElizabeth E HickeyManouchehr KhazandiEmma PeelKatherine BelovAlexandra BoileauSanjay GargHenrietta VenterWei Yee ChanPeter B HillStephen W PageAllison J CowinDarren J TrottThere are very few articles in the literature describing continuous models of bacterial infections that mimic disease pathogenesis in humans and animals without using separate cohorts of animals at each stage of disease. In this work, we developed bioluminescent mouse models of partial-thickness scald wound infection and sepsis that mimic disease pathogenesis in humans and animals using a recombinant luciferase-expressing Staphylococcus aureus strain (Xen29). Two days post-scald wound infection, mice were treated twice daily with a 2% topical mupirocin ointment for 7 days. For sepsis experiments, mice were treated intraperitoneally with 6 mg/kg daptomycin 2 h and 6 h post-infection and time to moribund monitored for 72 h. Consistent bacterial burden data were obtained from individual mice by regular photon intensity quantification on a Xenogen IVIS Lumina XRMS Series III biophotonic imaging system, with concomitant significant reduction in photon intensities in drug-treated mice. Post-mortem histopathological examination of wounds and bacterial counts in blood correlated closely with disease severity and total flux obtained from Xen29. The bioluminescent murine models provide a refinement to existing techniques of multiple bacterial enumeration during disease pathogenesis and promote animal usage reduction. The models also provide an efficient and information-rich platform for preclinical efficacy evaluation of new drug classes for treating acute and chronic human and animal bacterial infections.http://europepmc.org/articles/PMC6047774?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Abiodun D Ogunniyi
Zlatko Kopecki
Elizabeth E Hickey
Manouchehr Khazandi
Emma Peel
Katherine Belov
Alexandra Boileau
Sanjay Garg
Henrietta Venter
Wei Yee Chan
Peter B Hill
Stephen W Page
Allison J Cowin
Darren J Trott
spellingShingle Abiodun D Ogunniyi
Zlatko Kopecki
Elizabeth E Hickey
Manouchehr Khazandi
Emma Peel
Katherine Belov
Alexandra Boileau
Sanjay Garg
Henrietta Venter
Wei Yee Chan
Peter B Hill
Stephen W Page
Allison J Cowin
Darren J Trott
Bioluminescent murine models of bacterial sepsis and scald wound infections for antimicrobial efficacy testing.
PLoS ONE
author_facet Abiodun D Ogunniyi
Zlatko Kopecki
Elizabeth E Hickey
Manouchehr Khazandi
Emma Peel
Katherine Belov
Alexandra Boileau
Sanjay Garg
Henrietta Venter
Wei Yee Chan
Peter B Hill
Stephen W Page
Allison J Cowin
Darren J Trott
author_sort Abiodun D Ogunniyi
title Bioluminescent murine models of bacterial sepsis and scald wound infections for antimicrobial efficacy testing.
title_short Bioluminescent murine models of bacterial sepsis and scald wound infections for antimicrobial efficacy testing.
title_full Bioluminescent murine models of bacterial sepsis and scald wound infections for antimicrobial efficacy testing.
title_fullStr Bioluminescent murine models of bacterial sepsis and scald wound infections for antimicrobial efficacy testing.
title_full_unstemmed Bioluminescent murine models of bacterial sepsis and scald wound infections for antimicrobial efficacy testing.
title_sort bioluminescent murine models of bacterial sepsis and scald wound infections for antimicrobial efficacy testing.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2018-01-01
description There are very few articles in the literature describing continuous models of bacterial infections that mimic disease pathogenesis in humans and animals without using separate cohorts of animals at each stage of disease. In this work, we developed bioluminescent mouse models of partial-thickness scald wound infection and sepsis that mimic disease pathogenesis in humans and animals using a recombinant luciferase-expressing Staphylococcus aureus strain (Xen29). Two days post-scald wound infection, mice were treated twice daily with a 2% topical mupirocin ointment for 7 days. For sepsis experiments, mice were treated intraperitoneally with 6 mg/kg daptomycin 2 h and 6 h post-infection and time to moribund monitored for 72 h. Consistent bacterial burden data were obtained from individual mice by regular photon intensity quantification on a Xenogen IVIS Lumina XRMS Series III biophotonic imaging system, with concomitant significant reduction in photon intensities in drug-treated mice. Post-mortem histopathological examination of wounds and bacterial counts in blood correlated closely with disease severity and total flux obtained from Xen29. The bioluminescent murine models provide a refinement to existing techniques of multiple bacterial enumeration during disease pathogenesis and promote animal usage reduction. The models also provide an efficient and information-rich platform for preclinical efficacy evaluation of new drug classes for treating acute and chronic human and animal bacterial infections.
url http://europepmc.org/articles/PMC6047774?pdf=render
work_keys_str_mv AT abiodundogunniyi bioluminescentmurinemodelsofbacterialsepsisandscaldwoundinfectionsforantimicrobialefficacytesting
AT zlatkokopecki bioluminescentmurinemodelsofbacterialsepsisandscaldwoundinfectionsforantimicrobialefficacytesting
AT elizabethehickey bioluminescentmurinemodelsofbacterialsepsisandscaldwoundinfectionsforantimicrobialefficacytesting
AT manouchehrkhazandi bioluminescentmurinemodelsofbacterialsepsisandscaldwoundinfectionsforantimicrobialefficacytesting
AT emmapeel bioluminescentmurinemodelsofbacterialsepsisandscaldwoundinfectionsforantimicrobialefficacytesting
AT katherinebelov bioluminescentmurinemodelsofbacterialsepsisandscaldwoundinfectionsforantimicrobialefficacytesting
AT alexandraboileau bioluminescentmurinemodelsofbacterialsepsisandscaldwoundinfectionsforantimicrobialefficacytesting
AT sanjaygarg bioluminescentmurinemodelsofbacterialsepsisandscaldwoundinfectionsforantimicrobialefficacytesting
AT henriettaventer bioluminescentmurinemodelsofbacterialsepsisandscaldwoundinfectionsforantimicrobialefficacytesting
AT weiyeechan bioluminescentmurinemodelsofbacterialsepsisandscaldwoundinfectionsforantimicrobialefficacytesting
AT peterbhill bioluminescentmurinemodelsofbacterialsepsisandscaldwoundinfectionsforantimicrobialefficacytesting
AT stephenwpage bioluminescentmurinemodelsofbacterialsepsisandscaldwoundinfectionsforantimicrobialefficacytesting
AT allisonjcowin bioluminescentmurinemodelsofbacterialsepsisandscaldwoundinfectionsforantimicrobialefficacytesting
AT darrenjtrott bioluminescentmurinemodelsofbacterialsepsisandscaldwoundinfectionsforantimicrobialefficacytesting
_version_ 1725021442374893568